Int J Biol Sci 2020; 16(10):1718-1723. doi:10.7150/ijbs.45123

Review

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

Guangyu Zhou1,2, Qi Zhao1,2✉

1. Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China.
2. Institute of Translational Medicine, University of Macau, Taipa, Macau SPR, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci 2020; 16(10):1718-1723. doi:10.7150/ijbs.45123. Available from http://www.ijbs.com/v16p1718.htm

File import instruction

Abstract

A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.

Keywords: Neutralizing antibody, SARS-CoV-2, COVID-19, severe acute respiratory syndrome